Xuanzhu Biopharm set for spin-off in Hong Kong IPO
The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines Key Takeaways: Xuanzhu…
Recent Articles
RECENT ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
